Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,454,937,946Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry under nu ...

·邓白氏报告显示，印度2026财年第一季度GDP同比大增7.8%，工业产值指数（IIP）7月增长3.5%，其 中基础金属、电气设备及非金属矿物制品等制造业板块表现尤为亮眼。受益于建筑需求稳定与低基数效 应，8月IIP增速预计进一步升至6%。印度央行维持5.5%回购利率及中性立场，流动性持续过剩，通过 市场操作吸收1.79万亿卢比。10年期国债收益率稳定于6.4%，短端利率持稳。卢比汇率预计9月小幅走 强至87.2兑1美元（8月为87.4）。 ·BlueBay首席投资官指出，市场消息称特朗普无意提名"特立独行"的外部人士担任美联储主席，此消息 或为美债投资者带来信心，有助于稳定长期国债收益率，缓解政策不确定性风险。美联储降息周期启动 在即，幅度预期温和：市场普遍预计，美联储将在下周FOMC会议上启动降息，大概率降息25个基点， 降息50基点的可能性较低。随着宽松周期重启，短端利率有望率先回落，推动收益率曲线形态修复。 ·桑坦德银行策略师指出，尽管不应完全排除降息可能，但欧洲央行短期内大概率将维持存款利率在 2.00%不变，直至今年晚些时候等待关键宏观数据验证其经济预测。欧洲央行并无必要将利率降至2%以 下，暗示 ...

Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration Designation earned for a one-time intravitreal gene therapy with the potential to eliminate treatment burden for people living with neovascular age-related macular degenerationNeovascular or “wet” age-related macular degeneration can lead to significant vision loss and affects more than one million people in the US Paris, September 11, 2025. The US Food and Drug Administration (FDA) has granted fast tr ...

Sabadell CEO Cesar Gonzalez-Bueno expects BBVA to improve its initial takeover bid for Sabadell Bank, as the current offer undervalues the institution, reported Reuters. His remarks came following BBVA's official initiation of a takeover bid for Sabadell earlier this week. Gonzalez-Bueno remarked at a financial event organised by Barclays in New York, “This offer is most probably not the last one, because everybody agrees that this offer lacks merits.” During the same event BBVA's CEO Onur Genç describe ...

Group 1 - The U.S. Commodity Futures Trading Commission (CFTC) has announced charges against multiple firms for compliance violations, resulting in a total fine of $8.3 million [1] - Citigroup was fined $1.5 million for failing to submit accurate large trader reports from at least 2015 to 2022 and for not maintaining regulatory records for 10 weeks in 2023 [1] - UBS was penalized $5 million for inadequate supervision of its trading monitoring program from at least 2015 to 2024 [1] Group 2 - SMBC Capital Markets, Santander Bank, and Bank of New York Mellon were each fined $500,000 for record-keeping and supervision violations [1] - The CFTC stated that the involved companies have completed or are nearing completion of remedial measures and have agreed to avoid further violations of the Commodity Exchange Act and CFTC regulations [1]

Core Insights - Amlitelimab, a monoclonal antibody targeting OX40-ligand, met all primary and key secondary endpoints in the COAST 1 phase 3 study for atopic dermatitis, showing significant skin clearance and reduced disease severity compared to placebo at Week 24 [1][2][5] - The study demonstrated that amlitelimab can be administered every four or twelve weeks, potentially allowing for only four doses per year, which may represent a significant advancement in treatment options for atopic dermatitis [2][5][10] Study Details - The COAST 1 study was a randomized, double-blind, placebo-controlled trial involving 601 participants aged 12 years and older with moderate-to-severe atopic dermatitis, conducted across 15 countries [9] - Key endpoints included the proportion of patients achieving a validated investigator global assessment scale for AD (vIGA-AD) of 0 or 1 and a reduction from baseline score of ≥2 points, as well as a 75% or greater improvement in the eczema area and severity index total score (EASI-75) [2][3][9] Efficacy Results - At Week 24, 21.1% of patients on Q4W and 22.5% on Q12W achieved vIGA-AD 0/1 compared to 9.2% in the placebo group, with p-values <0.01 [3] - EASI-75 was achieved by 35.9% of patients on Q4W and 39.1% on Q12W, compared to 19.1% in the placebo group, with p-values <0.001 [3] Safety Profile - Amlitelimab was well-tolerated, with no new safety concerns identified; the most common treatment-emergent adverse events were mild and included atopic dermatitis, nasopharyngitis, and upper respiratory tract infection, all more common in the placebo group [7][8] - Injection site reactions were slightly higher in the amlitelimab arms (2.2%) compared to placebo (0.7%), but all were mild and resolved without discontinuation of the study medication [7] Future Outlook - Additional phase 3 results from the OCEANA clinical development program, which includes COAST 1 and four other studies, are expected through 2026 and will inform potential global regulatory submissions [8][10] - Amlitelimab is under clinical investigation and has not yet been evaluated by any regulatory authority [8]

Core Insights - The US FDA has approved Wayrilz (rilzabrutinib) for adults with persistent or chronic immune thrombocytopenia (ITP) who have not responded adequately to previous treatments, based on the successful LUNA 3 phase 3 study [1][3] - Wayrilz is a novel oral Bruton's tyrosine kinase (BTK) inhibitor that targets multiple immune pathways to address the underlying causes of ITP [2][11] - The approval highlights Sanofi's commitment to developing innovative therapies for rare and immunological diseases [3][11] Study Results - The LUNA 3 study involved 202 adult patients and demonstrated that 64% of patients on Wayrilz achieved a platelet count response at 12 weeks compared to 32% in the placebo group [3][10] - Patients on Wayrilz reported a 10.6-point improvement in health-related quality of life measures, while the placebo group showed a 2.3-point increase [4] - Statistically significant results included a durable platelet response at week 25 (23% in Wayrilz vs. 0% in placebo; p<0.0001) and a faster time to first platelet response (36 days in Wayrilz vs. not reached in placebo; p<0.0001) [7] Treatment Implications - Wayrilz offers a new treatment option for patients who have not responded to steroids or existing therapies, potentially improving management of ITP [5][11] - The drug has received Fast Track and Orphan Drug Designations from the FDA for ITP and is under regulatory review in the EU and China [8][12] - Sanofi's HemAssist program will provide support for patients undergoing treatment with Wayrilz, including assistance with access and insurance coverage [9] Company Overview - Sanofi is an R&D driven biopharma company focused on innovative therapies for various diseases, including rare and immunological conditions [13] - The company is committed to leveraging its understanding of the immune system to develop effective treatments and improve patient outcomes [13]

Core Viewpoint - Goldman Sachs downgraded Deutsche Bank's rating from "Buy" to "Neutral" and Deutsche Commercial Bank's rating from "Neutral" to "Sell" due to their stock performance exceeding the market since the beginning of the year [1] Group 1: Market Performance - The European banking sector has risen nearly 50% year-to-date, significantly outperforming the overall European stock market [1] - Factors contributing to this growth include strong growth momentum, a more stable and steeper interest rate trajectory, and ongoing performance growth and rating upgrades [1] Group 2: Analyst Outlook - Goldman Sachs maintains an optimistic outlook for European banks, projecting an average potential stock price increase of about 10% over the next 12 months, with some stocks rated "Buy" expected to rise by approximately 20% [1] - Stocks rated "Buy" include UBS Group, ING Group, Lloyds Banking Group, BNP Paribas, National Westminster Group, Santander Bank, and HSBC [1] Group 3: Interest Rate Environment - The interest rate curve has steepened this year, with expectations for final rates trending towards a range-bound movement, enhancing investor confidence in the medium-term outlook for net interest income [1]

Banco Santander is leading a roughly $2.7 billion debt deal to support Thoma Bravo’s acquisition of customer-service automation business Verint, according to sources https://t.co/sAMFsgXoDH ...

Group 1 - The total number of issued shares for Sanofi as of July 31, 2025, is 1,227,468,973 [1] - The number of real voting rights, excluding treasury shares, is 1,353,375,756 [1] - The theoretical number of voting rights, including treasury shares, is 1,361,835,529 [1] Group 2 - Sanofi is a French société anonyme with a registered share capital of €2,454,937,946 [1] - The company is registered at the Paris Commercial and Companies Registry under number 395 030 844 [1] - Additional information regarding shares and voting rights is available on Sanofi's official website [2]